Recursion Couples $200 Million Financing with Clinical and Partner Milestones
Late catch from 15 October: Recursion announced a $200 million underwritten follow-on offering, updated human data for REC-4881 and the RBM39 degrader REC-1245, and Sanofi’s option of the first development candidate from their collaboration….
